BYD
26.2.2024 03:44:26 CET | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles and power battery, proudly unveils the first pure electric supercar model U9 under its high-end sub-brand, YANGWANG, priced at 1.68 million RMB, and announced the delivery will start in this summer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240225803324/en/
YANGWANG U9 (Photo: Business Wire)
Adopting the “Time Gate” design language, the YANGWANG U9 embodies a distinctive aesthetic, characterized by unique proportions, tension, and power, reflecting its identity as a pure electric supercar.
Robust Technologies Shapes The Track-ready, Street-savvy, and Playful U9
The YANGWANG U9 is powered by two core technologies, the e4 platform and the DiSus-X Intelligent Body Control System, revolutionizing the pure electric supercar segment, seamlessly integrating track performance, street adaptability, and playful features.
The e4 Platform is a power system with four independent electric motors as its core, featuring agile and precise and four-wheel independent torque output control, bringing users the ultimate in safety, performance, and experience. The YANGWANG U9 packs a whopping 1,300 horsepower and a maximum torque of 1680N·m.
The BYD DiSus-X Intelligent Body Control System is another proprietary breakthrough. The first deployment of the BYD DiSus-X Intelligent Body Control System enables the YANGWANG U9 to achieve the maximum adjustable suspension travel of up to 75mm, while its peak single-axis lifting speed of up to 500mm/s, enabling instantaneous lifting force of over 1 ton and facilitating the remarkable leap-up of the U9. Those features deliver unparalleled driving experience in diverse driving scenarios like braking, acceleration, cornering, and road impacts, greatly enhancing vehicle agility and comfort for both drivers and passengers. In addition to these, YANGWANG U9 can effortlessly dance to music with just a click.
Unprecedented Performance Redefines Pure Electric Supercar
In recent tests, the YANGWANG U9 reaches a top speed of 309.19 km/h and can sprint from 0 to 100 km/h in just 2.36 seconds, with 0-400m acceleration in only 9.78 seconds. Besides, after rigorous track testing, the U9 has fine-tuned its thermal management system to better resist high temperatures, resulting in a 100% increase in maximum cooling capacity. The Blade Battery facilitates discharging and cooling functions and Dual Plug-in Ultra-fast charging technology boasts a maximum charging power of 500 kW. Additionally, YANGWANG U9 is equipped with 12 sets of active and passive aerodynamic packages to reduce drag coefficient and enhance heat dissipation efficiency.
The YANGWANG U9 boasts the Super Carbon-fiber Cabin, a structure made of different materials, and the next-generation CTB technology. And it contributes to unprecedented torsional stiffness of 54425N·m/deg and the single-side compressive load of the roof exceeds 11 tons, ensuring comprehensive travel safety.
Intelligent Cabin Creates Unparalleled Driving Experience
The YANGWANG U9 is equipped with the DiLink150 intelligent platform, powered by customized 4nm 5G chips. Specifically designed for track driving, it boasts an intelligent racing assistantance, providing extensive track driving services with detailed information on nearly 30 racetracks across China.
Inside, the YANGWANG U9’s cockpit features two 14-way adjustable seats to offer drivers and passengers with better experience. It also boasts the Dynaudio Evidence Series high-end audio system, offering an immersive auditory experience.
With BYD's adhering commitments to innovation and sustainability, YANGWANG redefines the essence of the supercar with its cutting-edge technologies and superior performance, offering uncompromising safety and an incomparable driving experience to users.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, and electronic controllers. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e4 Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world's first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 11 years in a row. For more information, please visit www.byd.com.
Please download the press kit via https://we.tl/t-r0AB5Tylah
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240225803324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom